title: Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial.
abstract: BACKGROUND
  Neuroinflammation is thought to be important in Alzheimer's disease pathogenesis. Mast cells are a key component of the inflammatory network and participate in the regulation of the blood-brain barrier's permeability. Masitinib, a selective oral tyrosine kinase inhibitor, effectively inhibits the survival, migration and activity of mast cells. As the brain is rich in mast cells, the therapeutic potential of masitinib as an adjunct therapy to standard care was investigated.
  
  
  METHODS
  A randomised, placebo-controlled, phase 2 study was performed in patients with mild-to-moderate Alzheimer's disease, receiving masitinib as an adjunct to cholinesterase inhibitor and/or memantine. Patients were randomly assigned to receive masitinib (n = 26) (starting dose of 3 or 6 mg/kg/day) or placebo (n = 8), administered twice daily for 24 weeks. The primary endpoint was change from baseline in the Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-Cog) to assess cognitive function and the related patient response rate.
  
  
  RESULTS
  The rate of clinically relevant cognitive decline according to the ADAS-Cog response (increase >4 points) after 12 and 24 weeks was significantly lower with masitinib adjunctive treatment compared with placebo (6% vs. 50% for both time points; P = 0.040 and P = 0.046, respectively). Moreover, whilst the placebo treatment arm showed worsening mean ADAS-Cog, Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory, and Mini-Mental State Examination scores, the masitinib treatment arm reported improvements, with statistical significance between treatment arms at week 12 and/or week 24 (respectively, P = 0.016 and 0.030; P = 0.035 and 0.128; and P = 0.047 and 0.031). The mean treatment effect according to change in ADAS-Cog score relative to baseline at weeks 12 and 24 was 6.8 and 7.6, respectively. Adverse events occurred more frequently with masitinib treatment (65% vs. 38% of patients); however, the majority of events were of mild or moderate intensity and transitory. Severe adverse events occurred at a similar frequency in the masitinib and placebo arms (15% vs. 13% of patients, respectively). Masitinib-associated events included gastrointestinal disorders, oedema, and rash.
  
  
  CONCLUSIONS
  Masitinib administered as add-on therapy to standard care during 24 weeks was associated with slower cognitive decline in Alzheimer's disease, with an acceptable tolerance profile. Masitinib may therefore represent an innovative avenue of treatment in Alzheimer's disease. This trial provides evidence that may support a larger placebo-controlled investigation.
  
  
  BACKGROUND
  Clinicaltrials.gov NCT00976118.
authors.affiliation: Hôpital Charles Foix, Service de Médecine, Bâtiment Louis Ramond, 7 avenue de la République, 94205 Ivry-Sur-Seine, France. francois.piette@cfx.aphp.fr.
authors.forename: François
authors.initials: F
authors.lastname: Piette
authors.forename: Joël
authors.initials: J
authors.lastname: Belmin
authors.forename: Hélène
authors.initials: H
authors.lastname: Vincent
authors.forename: Nicolas
authors.initials: N
authors.lastname: Schmidt
authors.forename: Sylvie
authors.initials: S
authors.lastname: Pariel
authors.forename: Marc
authors.initials: M
authors.lastname: Verny
authors.forename: Caroline
authors.initials: C
authors.lastname: Marquis
authors.forename: Jean
authors.initials: J
authors.lastname: Mely
authors.forename: Laurence
authors.initials: L
authors.lastname: Hugonot-Diener
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Kinet
authors.forename: Patrice
authors.initials: P
authors.lastname: Dubreuil
authors.forename: Alain
authors.initials: A
authors.lastname: Moussy
authors.forename: Olivier
authors.initials: O
authors.lastname: Hermine